Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Prevalence of Chronic Diseases and Lifestyle-related Disorders
4.2.2 Increase in Data Management and Connectivity through Interoperability to Electronic Health Record (EHR)
4.2.3 Rising Demand for Early Diagnosis and Treatment
4.2.4 Rising Adoption of Telehealth Services and Remote Communications
4.3 Market Restraints
4.3.1 High Cost of Molecular Diagnostics Tools
4.3.2 Lack of Skilled Professionals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Flow Cytometry
5.1.2 Hematology Test
5.1.3 Microbiology and Infectious Test
5.1.4 Coagulation Test
5.1.5 Immunoprotein
5.1.6 Routine and Special Chemistry
5.1.7 Others
5.2 By End User
5.2.1 Operating Room
5.2.2 Emergency Room
5.2.3 Intensive Care Unit
5.2.4 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott
6.1.2 Bayer AG
6.1.3 Becton, Dickinson & Company
6.1.4 bioMerieux SA
6.1.5 Bio-Rad Laboratories, Inc.
6.1.6 Chembio Diagnostic Systems, Inc.
6.1.7 Danaher Corporation
6.1.8 F. Hoffmann-La Roche
6.1.9 Siemens Healthineers
6.1.10 Sysmex Corporation


7 MARKET OPPORTUNITIES AND FUTURE TRENDS